Endothelial nitric oxide synthase activity is inhibited by the plasma membrane calcium ATPase in human endothelial cells. by Holton, Marylouisa et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Endothelial nitric oxide synthase activity is inhibited
by the plasma membrane calcium ATPase
in human endothelial cells
MaryLouisa Holton 1, Tamer M.A. Mohamed2,3, Delvac Oceandy2, Weiguang Wang4,
Santiago Lamas5, Michael Emerson6, Ludwig Neyses2, and Angel L. Armesilla1*
1Molecular Pharmacology Group, Department of Pharmacy, Research Institute in Healthcare Sciences, School of Applied Sciences, University of Wolverhampton, Wulfruna Street,
Wolverhampton WV1 1SB, UK; 2Cardiovascular Research Group, School of Clinical and Laboratory Sciences, Biomedical Research Centre, Central Manchester NHS Foundation Trust,
University of Manchester, Manchester, UK; 3Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt; 4Oncology Group, Research Institute in Healthcare
Sciences, School of Applied Sciences, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1SB, UK; 5Laboratorio Mixto CSIC-FRIAT de Fisiopatologı´a Vascular y Renal,
Centro de Investigaciones Biolo´gicas (CIB-CSIC), Fundacio´n Renal In˜igo Alvarez de Toledo, Ramiro de Maeztu 9, 28040 Madrid, Spain; and 6National Heart and Lung Institute, Imperial
College London, Exhibition Road, London SW7 2AZ, UK
Received 14 September 2009; revised 12 February 2010; accepted 2 March 2010; online publish-ahead-of-print 7 March 2010
Time for primary review: 35 days
Aims Nitric oxide (NO) plays a pivotal role in the regulation of cardiovascular physiology. Endothelial NO is mainly pro-
duced by the endothelial nitric oxide synthase (eNOS) enzyme. eNOS enzymatic activity is regulated at several levels,
including Ca2+/calmodulin binding and the interaction of eNOS with associated proteins. There is emerging evidence
indicating a role for the plasma membrane calcium ATPase (PMCA) as a negative regulator of Ca2+/calmodulin-
dependent signal transduction pathways via its interaction with partner proteins. The aim of our study was to inves-
tigate the possibility that the activity of eNOS is regulated through its association with endothelial PMCA.
Methods
and results
We show here a novel interaction between endogenous eNOS and PMCA in human primary endothelial cells. The
interaction domains were located to the region 735–934 of eNOS and the catalytic domain of PMCA. Ectopic
expression of PMCA in endothelial cells resulted in an increase in phosphorylation of the residue Thr-495 of
endogenous eNOS. However, disruption of the PMCA–eNOS interaction by expression of the PMCA interaction
domain significantly reversed the PMCA-mediated effect on eNOS phosphorylation. These results suggest that
eNOS activity is negatively regulated via interaction with PMCA. Moreover, NO production by endothelial cells
was significantly reduced by ectopic expression of PMCA.
Conclusion Our results show strong evidence for a novel functional interaction between endogenous PMCA and eNOS in endo-
thelial cells, suggesting a role for endothelial PMCA as a negative modulator of eNOS activity, and, therefore, NO-
dependent signal transduction pathways.
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1. Introduction
Cardiovascular disease, one of the leading causes of mortality in
western populations, encompasses a number of different conditions
including coronary heart disease, stroke, and peripheral vascular
disease. The underlying pathology for all these disorders is associated
with endothelial dysfunction.1 Under normal conditions, the cells of
the vascular endothelium transmit extracellular signals to the arterial
wall to regulate cardiovascular physiology. The ability of the
endothelium to synthesize and release the vasodilator nitric oxide
plays a major role in this process.
In endothelial cells, NO is synthesized from the amino acid L-arginine
and molecular oxygen by the constitutively expressed endothelial form
of nitric oxide synthase (eNOS or NOS3).2 Normal function of eNOS
and the tonic production of NO are associated with a fully functional
endothelium. In contrast, reduced bioavailability of NO is thought to
be one of the central factors common to vascular disease.1 eNOS
enzymatic activity is regulated at different levels including Ca2+/
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calmodulin binding,3 post-translational lipid modifications,4 multi-site
phosphorylation5 and its association with partner proteins.4
Studies in recent years have uncovered an increasingly important
role for the plasma membrane calcium ATPase (PMCA) pump as a
novel regulator of Ca2+/calmodulin-dependent signal transduction
pathways via interaction with specific partner proteins.6 PMCAs are
enzymatic low capacity, high-affinity systems involved in the extrusion
of Ca2+ from the cell.7 Four different PMCA isoforms, PMCA1–4,
have been identified in mammals and are encoded by four indepen-
dent genes.8 It is thought that PMCA regulates the activity of associ-
ated proteins by tethering them to low Ca2+/calmodulin cellular
microdomains created by the Ca2+ extrusion activity of the pump.
In this sense, PMCA has been shown to interact and inhibit the activity
of the Ca2+/calmodulin-dependent proteins nNOS,9 –11 CASK,12 and
calcineurin.13– 15
The role of PMCA as a regulator of Ca2+/calmodulin-dependent
enzymes and, in particular, its involvement in the regulation of NO
production by nNOS in neuronal, cardiac, and smooth muscle
cells9 –11 prompted us to investigate the hypothesis that the activity
of eNOS is regulated through its association with endothelial PMCA.
Here we show a novel interaction between endogenous PMCAs
and eNOS in human umbilical vein endothelial cells (HUVEC) and
human dermal microvascular endothelial cells (HDMEC). PMCA
expression in HUVEC and HDMEC leads to a significant increase in
the phosphorylation of residue Thr-495 of eNOS. Conversely,
ectopic expression of PMCA results in a slight reduction on the phos-
phorylation of Ser-1177. Disruption of the PMCA–eNOS interaction
(by expression of the PMCA interaction domain) reversed the PMCA-
mediated increase in eNOS Thr-495 phosphorylation, demonstrating
the functionality of this interaction. These PMCA-dependent modifi-
cations in the phosphorylation status of key regulatory residues of
eNOS suggest that eNOS activity is negatively regulated via inter-
action with PMCA. In agreement with this hypothesis, expression of
PMCA in HUVEC resulted in a significant reduction in NO production
by endothelial cells.
Our results reinforce the emerging role of PMCA as a macromol-
ecular complex organizer and a modulator of Ca2+/calmodulin-
dependent signal transduction pathways. Moreover, this work
reveals eNOS as a new interaction partner of PMCA and suggests a
role for PMCA as a regulator of NO production by endothelial
cells, what might open new avenues for future therapeutic approaches
to treat patients suffering from cardiovascular diseases.
2. Methods
2.1 Cell culture
HEK 293 cells were maintained in Dulbecco’s modified Eagle’s medium
(Sigma-Aldrich) supplemented with 10% foetal calf serum, 1% penicillin/
streptomycin and 1% L-glutamine. HUVEC (Clonetics or Promocell)
were maintained in Endothelial Cell Growth Medium 2-Supplement mix
(Promocell) supplemented with 1% penicillin/streptomycin. HDMEC
(Promocell) were maintained in Endothelial Cell Growth Medium
MV-Supplement mix (Promocell) supplemented with 1% penicillin/strep-
tomycin. Endothelial cells were used at low passage numbers (3–5).
2.2 Plasmids
pcDNA3-hPMCA2b contains the human PMCA2b cDNA and was a gift
from Professor Carafoli (University of Padova, Italy). pFlag-PMCA2b
(462–684) and pFlag-PMCA2b(1143–1243) have been described
previously.14 pcDNA3-hPMCA4b contains the human PMCA4b
cDNA.13 pFlag-PMCA4b(1–92) and pFlag-PMCA4b(428–651) have
been described previously.13 Plasmid pFlag-PMCA4b(652–840) has
been previously reported.16 pcDNA3-eNOS contains the human eNOS
cDNA. For details on the generation of plasmids pFlag-eNOS (401–
934), pFlag-eNOS (193–735), pFlag-eNOS (735–934), and pFlag-eNOS
(1–505), please see the expanded section Generation of plasmids in
the Supplementary material on line.
2.3 Transient transfections
For immunoprecipitation experiments, HEK 293 cells were plated in
100 × 20 mm2 tissue culture dishes (4.5 × 106 cells/plate) the day
before transfection. Cells were transfected with 10 mg of the indicated
expression plasmids by using LipofectAMINE 2000 reagent (Invitrogen)
as described previously.13
For transfection of primary endothelial cells, 1 × 106 HUVEC were
transfected with 5 mg of the indicated expression plasmids in 100 mL of
HUVEC nucleofector solution from a HUVEC nucleofector kit (Amaxa)
following the recommendations of the manufacturer. Likewise, 1 × 106
HDMEC were transfected with 5 mg of the indicated expression plasmids
in 100 mL of nucleofector solution from a Basic nucleofector Primary
Endothelial cells kit (Amaxa) following the recommendations of the man-
ufacturer. After transfection, endothelial cells were resuspended in fresh
media, plated in six-well tissue culture plates, and incubated overnight.
The following day, cells were washed with PBS and incubated for 24 h
more in 5 mL of endothelial medium with supplements.
2.4 cGMP and NO determination
For cGMP determination, transfected HUVEC were saturated with
L-arginine (30 min, 1 mM) and nascent NO was stabilized by addition of
superoxide dismutase (100 U/mL of culture medium) (Sigma-Aldrich)
5 min before lyses. In parallel, 3-isobutyl-L-methylxanthine (IBMX, 1 mM;
Sigma-Aldrich) was added to the culture 5 min before lyses (to inactivate
phosphodiesterase activity), and NO synthesis was induced by addition of
0.5 mM A23487 calcium ionophore 3 min before lyses. cGMP content was
determined by using a cGMP Enzymeimmunoassay BiotrakTM (EIA) system
(Amersham) according to the manufacturers instructions.
For the determination of intracellular nitric oxide bioavailability,
HUVEC were transfected as indicated earlier, except that cells were
plated on laminin-coated, glass-bottomed, black-walled 24-well plates.
After incubation, cells were loaded with 10 mM of the NO-sensitive fluor-
escence probe DAF-FM (Molecular Probes) at 378C for 30 min. The
medium, containing loading dye, was removed and replaced with 1 mL
of EGM-2 medium and incubated for another 45 min at 378C to ensure
complete de-esterification. NO synthesis was induced by stimulation
with acetylcholine (100 mM) for 5 min. Fluorescence was detected with
a live cell imaging Leica AS MDW inverted fluorescence microscope in
which the cells were kept at 378C. Relative fluorescence intensity per
cell was quantified using ImageJ software.
2.5 Immunoprecipitation
Primary endothelial cells (HUVEC, HDMEC) or transfected HEK293 cells
were lysed using RIPA buffer (1x PBS, 1% Igepal, 0.5% sodium deoxycho-
late, 0.1% SDS, 20 mM PMSF, 500 ng/mL leupeptin, 1.0 mg/mL aprotein,
500 ng/mL pepstatin). To minimize unspecific binding, 1 mL of protein
extracts were pre-cleared by incubation with 200 mL of protein
A-agarose beads (Roche) at 48C, for 1 h. Beads were removed by cen-
trifugation, and pre-cleared protein extracts were incubated overnight
with the corresponding immunoprecipitating antibodies and 40 mL of
protein A-agarose beads (Roche), at 48C, with shaking. Beads were
recovered by centrifugation at 3000 r.p.m. and washed three times with
500 mL of RIPA buffer. Washed beads were resuspended in 60 mL of
2x SDS–PAGE-loading buffer (Invitrogen) and analysed by western blot.
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2.6 Western blot
Samples were boiled and resolved as described previously.13 For a
detailed description of antibody sources and conditions for western
blot experiments, please see the expanded section Western blot anti-
bodies in the Supplementary material online.
2.7 Statistical analysis
Numerical data are expressed as mean+ SEM and were analysed for stat-
istical significance using Student’s t-test. The chosen significance criterion
was P, 0.05.
2.8 PMCA 4 knockdown in endothelial cells
HUVEC were plated on laminin-coated, glass-bottomed, black-walled
24-well plates. After overnight incubation at 378C, cells were infected
with Ad-PMCA4shRNA or Ad-CONTROLshRNA adenoviruses (MOI
25). Ad-PMCA4shRNA or Ad-CONTROLshRNA adenoviruses were
generated by cloning sequence shPMCA4 (CAACGTTCTGGACCTCA
TATTCAAGAGATATGAGGTCCAGAACGTTG) (encoding a short
hairpin RNA silencer for isoform PMCA4), or CONTROL (TTCT
CCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAA)
(irrelevant sequence used as a control), respectively, into plasmid
pSilencer-U6 (Invitrogen). The resulting plasmids were used to generate
recombinant adenoviruses Ad-PMCA4shRNA or Ad-CONTROLshRNA
by using the ViraPower Adenoviral Gateway system (Invitrogen) following
the recommendations of the manufacturer. Infected HUVEC were incu-
bated at 378C for 5 days before being analysed for NO production;
during this time, the culture medium was replaced by fresh medium
every 2 days. To measure intracellular NO levels, cells were loaded
with 10 mM of the NO-sensitive fluorescence probe DAF-FM (Molecular
Probes) at 378C for 30 min. The medium, containing loading dye, was
removed and replaced with 1 mL of EGM-2 medium and incubated for
another 45 min at 378C to ensure complete de-esterification. NO syn-
thesis was induced by stimulation with acetylcholine (100 mM) for 5 min.
3. Results
3.1 Endogenous PMCA and eNOS interact
in human endothelial cells
To investigate the interaction between endogenous PMCA and eNOS
in endothelial cells, protein extracts from primary HUVEC or
HDMEC were immunoprecipitated with the anti-PMCA 5F10
Figure 1 Endogenous PMCA and eNOS interact in human endothelial cells. (A) eNOS and PMCA co-precipitate in endothelial cells. (Left panels)
Protein lysates isolated from primary HUVEC or HDMEC were incubated with an anti-PMCA monoclonal antibody (5F10) and immunoprecipitated
proteins analysed by western blot with an anti-eNOS rabbit polyclonal antibody. (Right panels) Endothelial protein lysates were immunoprecipitated
with an anti-eNOS rabbit polyclonal antibody (a-eNOS) and immunoprecipitated proteins probed against the 5F10 anti-PMCA monoclonal antibody.
(B) PMCA isoforms 1, 2, and 4 are expressed in endothelial cells. Protein lysates isolated from HUVEC or HDMEC were precipitated with an anti-
PMCA monoclonal antibody (5F10) and precipitated proteins were probed with rabbit polyclonal antibodies recognizing specifically PMCA isoforms 1,
2, or 4. (C) Protein extracts isolated from HUVEC were immunoprecipitated with polyclonal antibodies recognizing specifically the isoforms 1
(a-PMCA1) or 2 (a-PMCA2) of PMCA. Immunoprecipitated proteins were probed with a mouse anti-eNOS antibody (Zymed). Likewise, protein
extracts were precipitated with the JA9 anti-PMCA4 monoclonal antibody (a-PMCA4) and immunoprecipitated proteins subsequently probed
with a rabbit anti-eNOS polyclonal antibody. In all cases, eNOS was present within the immunoprecipitated proteins, suggesting that PMCA 1, 2,
and 4 isoforms interact with eNOS in endothelial cells. Immunoprecipitation with an irrelevant antibody against firefly luciferase (a-Luc) was included
as a negative control in all immunoprecipitation experiments.
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monoclonal antibody (Abcam). Immunoprecipitated proteins were
probed by western blot with an anti-eNOS rabbit polyclonal antibody
(Sigma). eNOS co-precipitated with PMCA in protein extracts iso-
lated from both cellular types (Figure 1A, left panels). Converse immu-
noprecipitation of protein lysates with a rabbit polyclonal antibody
raised against eNOS (Sigma), and subsequent western blot with the
anti-PMCA 5F10 monoclonal antibody, showed co-precipitation of
PMCA proteins (Figure 1A, right panels). These results demonstrate
the interaction between endogenous eNOS and PMCA in human
endothelial cells.
PMCA1 and 4 isoforms have been reported to be expressed in
most tissues.7 PMCA2 has a more restricted expression profile and
it has been detected in the cardiovascular system.17 Therefore, we
decided to investigate whether these PMCA isoforms are expressed
in HUVEC and HDMEC. For this purpose, we immunoprecipitated
protein lysates isolated from these cellular types using the anti-PMCA
5F10 monoclonal antibody (that recognizes all PMCA isoforms).
Western blot of the immunoprecipitated proteins with rabbit polyclo-
nal antibodies reacting specifically with the isoforms 1, 2, or 4 of
PMCA (Swant) revealed the presence of isoforms 1, 2, and 4 in
human endothelial cells (Figure 1B).
In order to determine whether these PMCA isoforms interact with
eNOS, we immunoprecipitated protein extracts isolated from
HUVEC with polyclonal antibodies specific for PMCA1 or PMCA2
isoforms (Swant) and probed the immunoprecipitated proteins with
an anti-eNOS monoclonal antibody (Zymed). Likewise, HUVEC
protein lysates were immunoprecipitated with the JA9 anti-PMCA4
monoclonal antibody and immunoprecipitated proteins probed with
an anti-eNOS rabbit polyclonal antibody (Sigma). Immunoprecipita-
tion of specific PMCA isoforms resulted in co-precipitation of
eNOS in all the cases (Figure 1C).
These results further demonstrate the interaction between
endogenous PMCA and eNOS and indicate that isoforms PMCA1,
-2 and -4 interact with eNOS in endothelial cells.
Control immunoprecipitations carried out in each experiment using
an irrelevant antibody (anti-luciferase) precipitated no protein, con-
firming the selectivity of the interactions (Figure 1A–C).
3.2 The big, intracellular, catalytic domain
of PMCA interacts with eNOS
To map the domain of PMCA implicated in the interaction with
eNOS, we transfected HEK293 cells with plasmids pFlag-PMCA4b
(1–92), pFlag-hPMCA2b(1143–1243), pFlag-hPMCA2b(462–684),
pFlag-PMCA4b(428–651), pFlag-PMCA4b(652–840), or pFlag-
CMV7.1 empty (negative control). These plasmids encode PMCA
N-terminal or C-terminal cytoplasmic tails, or different regions of
its big catalytic intracellular domain. Commercially available
recombinant human eNOS (Sigma) was added to protein lysates of
the transfected cells, which were then immunoprecipitated with a
rabbit polyclonal antibody against eNOS (Sigma), and analysed by
western blot.
Flag-PMCA2(462–684), a Flag-tagged protein containing the prox-
imal part of the big intracellular domain of PMCA2b, and Flag-
PMCA4(428–651), containing the homologous region in PMCA4b,
strongly co-precipitated with eNOS (Figure 2, upper panels).
However, no precipitation was detected when Flag-PMCA4b(1–92),
Flag-PMCA2b(1143–1243), or Flag-PMCA4b(652–840), Flag-tagged
proteins containing the N-terminal intracellular domain of PMCA4b,
the C-terminal intracellular domain of PMCA2b, or the distal part
of the big intracellular domain of PMCA4b, respectively, were used
in the assayed (Figure 2, upper panels).
Figure 2 PMCA interacts with eNOS through the proximal part of the catalytic domain. Mapping of the region of PMCA involved in the interaction
with eNOS. Expression vectors encoding Flag-tagged PMCA2b(462–684), PMCA2b(1143–1243), PMCA4b(1–92), PMCA4b(428–651), or
PMCA4b(652–840) were transfected in HEK 293 cells. Transfection of p3xFlag-CMV7.1 empty vector (Sigma) (F-empty) was used as a negative
control. Protein lysates were incubated with commercial recombinant eNOS (Sigma) (10 mM, final concentration), and complexes were precipitated
with an anti-eNOS polyclonal antibody (Sigma). Flag-tagged immunoprecipitated proteins (upper panel) and the expression levels of the Flag-tagged
proteins prior to immunoprecipitation (lower panel) were analysed by western blot with anti-Flag antibody.
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All Flag-tagged PMCA-truncated proteins were expressed at
roughly equivalent levels (Figure 2, lower panels), thus ruling out the
scenario that poor expression led to the lack of interaction.
Cells transfected with empty vector p3xFlag-CMV7.1 were used as
a negative control (Figure 2, upper panel).
These results show that eNOS interacts with the proximal part
(amino acids 462–684 for PMCA2b, or 428–651 for PMCA4b) of
the PMCA catalytic, big intracellular loop located between transmem-
brane regions 4 and 5.
3.3 The region 735–934 of eNOS is
essential for interaction with PMCA
To map the domain of eNOS responsible for the interaction with
PMCA, a series of Flag-tagged deletion mutants of eNOS were gener-
ated (Figure 3A) and then assayed by immunoprecipitation for their
ability to interact with PMCA in mammalian cells. HEK 293 cells
were co-transfected with pcDNA3-hPMCA2b and either plasmid
pFlag-eNOS(401–934), pFlag-eNOS(193–735), or pFlag-eNOS(1–
505), and protein extracts were immunoprecipitated with the 5F10
anti-PMCA monoclonal antibody. A truncated version of eNOS con-
taining only amino acids 401–934 was still able to co-precipitate with
PMCA, indicating that the domain of eNOS implicated in the inter-
action with PMCA must be included within this region (Figure 3B,
upper panel). Overlapping mutants containing the regions 193–735
or 1–505 of eNOS failed to immunoprecipitate with PMCA
(Figure 3B, upper panel), suggesting that the region of eNOS 735–
934 is essential for the interaction with PMCA. In order to test this
hypothesis, we generated a new expression plasmid, pFlag-eNOS
(735–934), encoding a Flag-tagged version of eNOS containing
amino acids from 735 to 934, and we analyse its capacity to
interact with PMCA as described earlier. Flag-eNOS(735–934)
co-precipitated with PMCA in immunoprecipitation assays
(Figure 3C, upper panel).
Levels of the Flag proteins prior to immunoprecipitation were
analysed by western blot to ensure differences were not attributable
to differential expression of the fusion proteins (Figure 3B and C, lower
panels).
These results demonstrate that the region 735–934 of eNOS is
necessary and sufficient to maintain the interaction with PMCA.
3.4 PMCA modulates eNOS
phosphorylation in regulatory residues
Thr-495 and Ser-1177
Compelling evidence has recently revealed a novel role for PMCA
proteins as regulators of Ca2+/calmodulin-dependent enzymes.6 It is
thought that PMCA inhibits the activity of these enzymes by tethering
them to low calcium cellular microenvironments created by the
calcium extrusion function of PMCA. The identification of eNOS as
a PMCA interaction partner prompted us to investigate the functional
consequences of this interaction upon eNOS activity and, therefore,
NO production in endothelial cells.
Figure 3 Interaction with PMCA maps to the region 735–934 of eNOS. (A) Schematic representation of Flag-tagged deletion mutants of eNOS. (B)
Expression vectors encoding human PMCA2b and Flag-tagged deletion mutants of eNOS encoding amino acids 401–934, 193–735, or 1–505 were
co-transfected in HEK 293 cells. Protein lysates were incubated with the 5F10 anti-PMCA monoclonal antibody. Immunoprecipitated proteins (upper
panel) and the expression levels of Flag-tagged proteins prior to immunoprecipitation (lower panel) were probed by western blot with anti-Flag anti-
body. (C ) Expression vectors encoding human PMCA2b and Flag-tagged deletion mutants encoding amino acids 735–934 or 1–505 were
co-transfected in HEK 293 cells. Protein lysates were immunoprecipitated and probed by western blot as described in (B).
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Figure 4 PMCA modulates eNOS phosphorylation in regulatory residues Thr-495 and Ser-1177. (A) Ectopic expression of PMCA2b or 4b in endo-
thelial cells increases the phosphorylation status of endogenous eNOS in Thr-495. HUVEC or HDMEC were transfected with 5 mg of plasmids
pcDNA3-hPMCA2b, pcDNA-hPMCA4b, or p-cDNA3-Empty (negative control) and proteins analysed by western blot with a mouse antibody recog-
nizing specifically eNOS phosphorylated in the residue Thr-495 (a-eNOS(pT495)). Histogram shows data as mean+ SEM of seven independent
experiments performed with four different batches of cells. **P, 0.01. (B) Expression of PMCA2b in endothelial cells leads to a reduction in
eNOS Ser-1177 phosphorylation. HUVEC or HDMEC were transfected with 5 mg of plasmids pcDNA3-hPMCA2b or pcDNA3-Empty (negative
control). Transfected cells were incubated with VEGF (25 ng/mL) for the times indicated to induce phosphorylation of eNOS in Ser-1177 as
described.25 Protein lysates were analysed by western blot with a mouse antibody recognizing specifically eNOS phosphorylated in Ser-1177
(a-eNOS(pS1177). Histogram shows data as mean+ SEM of six independent experiments performed with four different batches of cells.
*P, 0.05, **P, 0.01. (C) Disruption of the PMCA–eNOS interaction reverses the PMCA-dependent effect on eNOS Thr-495 phosphorylation.
HMVEC (left panels) or HUVEC (right panels) were transfected with either 10 mg of empty vector; 5 mg of empty vector plus 5 mg of a vector encod-
ing PMCA2b or PMCA4b as indicated; or 5 mg of an expression vector for the indicated PMCA protein plus 5 mg of a pFlag vector encoding the
corresponding interaction domain. Western blot was performed as described in (A). Histogram shows data as mean+ SEM of five independent
experiments performed with three different batches of cells. **P, 0.01. In all experiments, total levels of eNOS protein were determined by analysing
lysates from transfected cells using a polyclonal rabbit anti-eNOS antibody (a-eNOS total).
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Multi-site phosphorylation is one of the mechanisms involved in the
regulation of eNOS activity.5 Phosphorylation at Ser-1177 of eNOS has
been shown to increase its activity, whereas phosphorylation at Thr-495
is inhibitory.5 To investigate the effect of ectopic expression of PMCA
on the activity of eNOS, we transfected HUVEC and HDMEC with an
expression vector encoding human PMCA2b or PMCA4b and analysed
by western blot the phosphorylation status of endogenous eNOS at
Thr-495 and Ser-1177 by using the corresponding phospho-specific
antibodies. Ectopic expression of PMCA2b in endothelial cells signifi-
cantly increased phosphorylation at Thr-495 of eNOS when compared
with that of control cells transfected with empty plasmid (Figure 4A,
upper panels). Likewise, ectopic expression of isoform PMCA4b
yielded an identical result (Figure 4A, upper panels). Phosphorylation
of Ser-1197 was, however, slightly reduced by ectopic expression of
PMCA2b in endothelial cells (Figure 4B, upper panels).
These results strongly suggest that PMCA negatively regulates
eNOS activity by promoting a significant increase in phosphorylation
of Thr-495 (inhibitory phosphorylation) and a slight decrease in phos-
phorylation of Ser-1177 (activating phosphorylation).
To investigative whether the interaction between PMCA and eNOS
plays a significant role in the observed increase in eNOS phosphorylation
at Thr-495, we blocked the interaction between PMCA and eNOS by
co-expressing PMCA2b or 4b, together with Flag-PMCA2(462–684)
or Flag-PMCA4(428–651), respectively. In both cases, blockage of the
PMCA–eNOS interaction (by overexpression of the corresponding
interaction domain) reversed the PMCA-mediated increase in Thr-495
phosphorylation (Figure 4C, upper panels). These results demonstrate
that the PMCA–eNOS interaction is essential for the PMCA-mediated
increase in eNOS inhibitory phosphorylation.
In all cases, the levels of total eNOS in the samples were analysed
using a rabbit polyclonal anti-eNOS antibody (Sigma) to rule out the
possibility that the differences detected in the phosphorylation levels
of eNOS were attributable to differential levels of the protein in the
samples after transfection (Figure 4A–C, lower panels).
3.5 PMCA significantly inhibits NO
production by endothelial cells
To determine whether the observed inhibitory effect exerted by
PMCA on eNOS activity led to a reduction on NO production in
endothelial cells, we transfected HUVEC with plasmid
pcDNA3-hPMCA2b or pcDNA3-hPMCA4b.
NO production was determined by measuring cGMP as a surrogate
marker. Ectopic expression of human PMCA2b in HUVEC resulted in
a significant reduction (43% inhibition, P ≤ 0.05) in NO production
when compared with the levels of NO produced by HUVEC trans-
fected with the pcDNA3-Empty vector (negative control)
(Figure 5A). To further confirm the decrease in NO production in
Figure 5 PMCA negatively regulates NO production in endothelial cells. Human PMCA2b or PMCA4b were ectopically expressed in HUVEC by
transfection of five mg of the corresponding expression vector (A). NO synthesis was induced by addition of the A23187 ionophore (0.5 mM) 3 min
before lyses. NO-dependent cGMP production was calculated in relation to HUVEC transfected with 5 mg of pcDNA3-Empty vector. Mean+ SEM
values of six independent experiments are shown. *P, 0.05. (B) Intracellular nitric oxide level in transfected HUVEC was assessed by staining cells
with the NO-sensitive dye DAF-FM. NO synthesis was stimulated by addition of acetylcholine (100 mM) for 5 min. Representative microscopy fields of
DAF-FM staining in cells are shown in left panels. Mean+ SEM values of fluorescence units measured from 25 different microscopy fields taken from
six independent preparations are shown. **P, 0.01.
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endothelial cells transfected with PMCA, intracellular NO levels were
measured by loading cells with 10 mM of the NO-sensitive fluor-
escence probe DAF-FM (Molecular Probes). NO synthesis was stimu-
lated by treating transfected cells with acetylcholine (100 mM) for
5 min. Acetylcholine-induced NO production in endothelial cells
expressing PMCA2b or PMCA4b was significantly lower (28.2 and
30.6%, respectively, P ≤ 0.01) than that of cells transfected with the
pcDNA3-Empty vector (Figure 5B).
Together, our results demonstrate a relevant role for PMCA as a
negative regulator of NO production in primary endothelial cells via
an inhibitory association with eNOS.
3.6 PMCA and calcineurin interact
in human endothelial cells
We have previously reported the interaction of PMCA with the Ca2+/
calmodulin-dependent phosphatase calcineurin in breast cancer
cells.14 The interaction in endothelial cells of PMCA with eNOS
(another Ca2+/calmodulin-dependent enzyme) that we show in this
work prompted us to investigate whether PMCA also interacts with
calcineurin in human endothelial cells. For this purpose, we immuno-
precipitated protein lysates from HUVEC with the 5F10 anti-PMCA
monoclonal antibody. Immunoprecipitated proteins were analysed
by western blot using antibodies recognizing specifically PMCA iso-
forms 1, 2, or 4. PMCA1, 2, and 4 were found within the immunopre-
cipitated proteins (Figure 6), demonstrating that endogenous PMCA
interacts with calcineurin in human endothelial cells.
4. Discussion
Through the production of NO, eNOS represents a crucial regulator
of cardiovascular physiology. In this work, we describe a novel role for
the plasma membrane Ca2+/calmodulin ATPase pump, PMCA, as a
negative regulator of NO production in endothelial cells. Endogenous
eNOS and PMCA interact in primary HUVEC and HDMEC, leading to
a decrease in eNOS activity and subsequent NO production by acti-
vated endothelial cells. In agreement with our observations on the
functional relevance of the PMCA–eNOS interaction as a novel
mechanism for eNOS regulation, inhibitory interactions between
eNOS and the intracellular domains of other plasma membrane pro-
teins such as caveolin-1,18 the bradykinin B2 receptor,19 the
endothelin-1 ETB receptor,20 and the angiotensin II AT1 receptor20
have been reported previously.
We demonstrate in this paper that PMCA1, 2, and 4 interact with
eNOS in endothelial cells (Figure 1C). The three isoforms have calcium
extrusion catalytic activity and, therefore, it is likely that there might
be redundancy in their function as negative regulators of eNOS. In
fact, supporting this hypothesis, knockdown of PMCA4 in endothelial
cells by infection with an adenovirus expressing a short hairpin RNA
silencer specific for PMCA4 did not alter NO production in either
basal or acetylcholine-stimulated conditions (see Supplementary
material on line, Figure S1).
The PMCA interaction domain is located in the proximal region of
the big intracellular catalytic domain defined by trans-membrane seg-
ments 4 and 5. PMCA2b and 4b interact with eNOS through the same
homologous region: 462–684 in PMCA2, or 428–651 in PMCA4
(Figure 2). Given the high percentage of amino acid homology
shown by the PMCA isoforms in this region, it is very likely that
PMCA1 also interacts with eNOS through the domain equivalent to
those mapped for PMCA2 and 4.
Our group has previously reported an inhibitory interaction
between endogenous PMCA and the Ca2+/calmodulin-dependent
phosphatase calcineurin A in breast cancer cells.14 In this work, we
demonstrate that PMCA also interacts with calcineurin A in human
endothelial cells. The interaction between PMCA and eNOS takes
place through the same domains of PMCA2 and 4 that reported for
the PMCA–calcineurin interaction.14 The interaction of another
Ca2+/calmodulin-dependent protein via the same domain of PMCA
suggests an important role for this region in the association with
partner proteins that are regulated by Ca2+.
We have also located the interaction domain with PMCA to the
region 735–934 of eNOS (Figure 3). An examination of the sequences
corresponding to the interaction domains in eNOS (this work) and
calcineurin A13 did not show any significant homology between the
two regions, suggesting that, probably, eNOS and calcineurin interact
with two different small fragments within the interaction domain of
PMCA. This leads to the intriguing possibility that PMCA, eNOS,
and calcineurin might be present in endothelial cells as a ternary
complex.
In this work, we demonstrate that ectopic expression of PMCA
results in a significant increment in the phosphorylation of residue
Thr-495 of eNOS (Figure 4A). The molecular mechanism behind the
PMCA-mediated increase in eNOS phosphorylation is not under-
stood at the moment. Interestingly, Harris et al.21 reported that calci-
neurin mediates dephosphorylation of Thr-495 of eNOS. We have
previously reported that PMCA inhibits calcineurin activity,13,14 thus,
if PMCA, calcineurin, and eNOS are part of a macromolecular
Figure 6 Endogenous PMCA and calcineurin interact in endo-
thelial cells. Protein lysates from HUVEC were incubated with an
anti-PMCA monoclonal antibody (5F10), anti-Luciferase antibody
(a-Luc), or an anti-calcineurin antibody (a-Cal) as indicated. Immu-
noprecipitated proteins were analysed by western blot with anti-
bodies recognizing specifically isoform 1 (a-PMCA1), 2
(a-PMCA2), or 4 (a-PMCA4) of PMCA. The presence of the
PMCA isoforms within the immunoprecipitated proteins indicates
that endogenous PMCA and calcineurin interact in endothelial cells.
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ternary complex, PMCA-dependent inhibition of calcineurin would
result in a decrease in calcineurin-mediated dephosphorylation of
Thr-495 contributing to eNOS inhibition. The possibility that
PMCA, calcineurin, and eNOS are forming a ternary macromolecular
complex, introducing a new level of regulation in NO production by
endothelial cells, requires further investigation. Supporting this
hypothesis, PMCA has been reported to participate in the organiz-
ation of a macromolecular protein complex formed by endogenous
PMCA, a-1 syntrophin, and nNOS in cardiac cells.22 Likewise,
eNOS has been found to be part of a ternary complex together
with caveolin-1 and NOSTRIN.23
Interestingly, when we disrupted the PMCA–eNOS interaction by
co-expressing PMCA together with the PMCA interaction domain,
the effect on eNOS Thr-495 phosphorylation was reversed
(Figure 4C). This result rules out the possibility that the PMCA inhibitory
effect on eNOS activity was due to general Ca2+ clearance resulting
from PMCA ectopic expression, and demonstrates the functional sig-
nificance of the PMCA–eNOS interaction. These data are in agreement
with the idea of PMCA inhibiting the activity of Ca2+/calmodulin-
dependent proteins by tethering them to low Ca2+/calmodulin cellular
microdomains created by the Ca2+ extrusion activity of the pump.
The role of Ca2+ in the PMCA–eNOS interaction is not known at
present, but it is tempting to speculate with the possibility that the
levels of intracellular Ca2+ could be implicated in the regulation of
the PMCA–eNOS interaction. In this context, it has been reported
that increments in the intracellular levels of Ca2+/calmodulin disrupt
the interaction between eNOS and caveolin-1, leading to the acti-
vation of eNOS.24 In a similar way, increments in intracellular Ca2+
levels might disrupt the PMCA–eNOS interaction leading to eNOS
activation. This increase in intracellular Ca2+ would also trigger
PMCA activation. As a result of PMCA activation, Ca2+ would be
removed around the PMCA microenvironment, and the local
reduction in intracellular Ca2+ levels would restore the interaction
between eNOS and PMCA, and the subsequent inhibition of eNOS
activity. The involvement of intracellular Ca2+ levels in the regulation
of the PMCA–eNOS interaction, and in the potential formation of a
ternary complex PMCA/eNOS/calcineurin, deserves further
investigation.
In conclusion, this work shows an inhibitory interaction between
endogenous PMCA and eNOS in human endothelial cells and suggests
PMCA as an important regulator of NO signalling in endothelial cells.
Considering the relevant role of NO in cardiovascular physiology and
pathophysiology, the implications of this interaction are far-reaching.
Loss of NO synthesis and bioavailability is a hallmark of cardiovascular
disease.1 Disruption of the PMCA–eNOS interaction might, there-
fore, have an important significance as a potential therapeutic target
to modulate NO bioactivity in patients with cardiovascular disease.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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